Physician profile
Todd H Wolynn
NPI 1205835592
$275,308.99
in general payments reported to CMS, 2019-2025
7 companies · $62K in 2025
The $62K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $31K · 2021: $27K · 2022: $21K · 2023: $32K · 2024: $36K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $76K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $19K · Food and Beverage: $2,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $75,839.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,934.00 |
| Travel and Lodging | $19,391.55 |
| Food and Beverage | $2,508.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $98,680.49 | 2019-2025 | Enflonsia, Gardasil 9 |
| Sanofi Pasteur INC. | $87,508.63 | 2019-2025 | |
| Modernatx, INC. | $39,505.31 | 2022-2025 | Moderna Covid-19 Vaccine, Mresvia |
| Seqirus USA INC | $18,678.48 | 2023-2024 | Flucelvax Quadrivalent |
| Pfizer INC. | $17,341.53 | 2021-2025 | |
| Novavax INC | $13,572.81 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Glaxosmithkline, LLC. | $21.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Wolynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.